Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms, Male × elacestrant × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Advanced Breast Cancer 2 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Endometrial Neoplasms 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Brain Neoplasms 1 Brain Diseases 1 Adenosarcoma of the uterus 1

Interventions

exemestane 3 Letrozole 3 Tamoxifen 2 Leuprolide 2 Immunotherapy 2 Goserelin 2 Anastrozole 2 ribociclib 1 elacestrant 1 Standard of Care 1 Practice Guidelines as Topic 1 Neoadjuvant Therapy 1 Methods 1 Interviews as Topic 1 Immunoenzyme Techniques 1 Genetic Counseling 1 Everolimus 1 Educational Status 1 Early Intervention, Educational 1 Blood Specimen Collection 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06492616 2026-03-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡